Protalix BioTherapeutics, Inc Form 8-K August 08, 2016			
UNITED STATES			
SECURITIES AND EXCH.	ANGE COMMISSION		
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 13	5(d) of		
the Securities Exchange Act	t of 1934		
Date of Report (Date of Ear	liest Event Reported): Augus	st 8, 2016	
Protalix BioTherapeutics, In (Exact name of registrant as			
	001 2225	(F.0(42FF2)	
Delaware (State or other jurisdiction	001-33357	65-0643773 (IRS Employer	
of incorporation)	(Commission File Number)	<b>Identification No.)</b>	

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

2 Snunit Street 20100 Science Park, POB 455 Carmiel, Israel (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

<sup>&</sup>quot;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

<sup>&</sup>quot;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

<sup>&</sup>quot;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

<sup>&</sup>quot;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Item 2.02. Results of Operations and Financial Condition

On August 8, 2016, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits

### (d) Exhibits

99.1 Press release dated August 8, 2016.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# PROTALIX BIOTHERAPEUTICS, INC.

Date: August 8, 2016 By: /s/ Moshe Manor

Name: Moshe Manor
Title: President and

Chief Executive Officer